- Title
- TP010/#1537 Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study
- Creators
- Ana Oaknin - Hebron UniversityDomenica Lorusso - Humanitas UniversityKlaus Pietzner - Charité - Universitätsmedizin BerlinJung-Yun Lee - Severance HospitalDavid Cibula - Charles UniversityYeh Chen Lee - Prince of Wales and Royal Hospital for Women, Randwick, AustraliaRussell Schilder - Thomas Jefferson UniversityAnnika Auranen - Tampere University HospitalBo Gao - Blacktown and Westmead Hospitals, Westmead, AustraliaDavid Tan - National University Cancer Institute, SingaporeAmit Oza - Princess Margaret Cancer CentreRowan Miller - St Bartholomew's HospitalVanda Salutari - Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Woman, Child and Public Health, Rome, ItalyGiulia Tasca - Istituto Oncologico VenetoDavid O’Malley - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteBradley Monk - Florida Cancer Specialists and Research Institute, West Palm Beach, USABhavana Pothuri - NYU Langone’s Laura and Isaac Perlmutter Cancer CenterLin Lu - Sutro BiopharmaCraig Berman - Sutro BiopharmaAnne Borgman - Sutro BiopharmaR. Wendel Naumann - Atrium Health Levine Cancer, Charlotte, USA
- Publication Details
- International journal of gynecological cancer, Vol.34, pp.A351-A351
- Publisher
- Elsevier Inc
- Identifiers
- 991006133436902656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
TP010/#1537 Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study
International journal of gynecological cancer, Vol.34, pp.A351-A351
10/2024
Metrics
1 Record Views